Free tool
FAERS Monitor: Provera
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 011839 or its brand name (Provera, Medroxyprogesterone Acetate). Reports on generic versions are filed under their own applications.
Reports
28,420
Serious
26,121
92% of reports
Hospitalization
3,170
Death reported
818
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- breast cancer female9,758
- breast cancer8,138
- breast cancer metastatic1,380
- meningioma854
- oestrogen receptor assay positive773
- progesterone receptor assay positive673
- pain521
- drug ineffective520
- breast cancer in situ516
- ovarian cancer499
- nausea470
- fatigue448
- headache391
- anxiety390
- cerebrovascular accident389
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3,215 |
| 2005 | 2,334 |
| 2006 | 1,804 |
| 2007 | 811 |
| 2008 | 1,983 |
| 2009 | 3,953 |
| 2010 | 6,981 |
| 2011 | 1,312 |
| 2012 | 567 |
| 2013 | 249 |
| 2014 | 234 |
| 2015 | 296 |
| 2016 | 316 |
| 2017 | 264 |
| 2018 | 299 |
| 2019 | 368 |
| 2020 | 407 |
| 2021 | 320 |
| 2022 | 301 |
| 2023 | 315 |
| 2024 | 445 |
| 2025 | 883 |
| 2026 | 762 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,025,739 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| progesterone receptor assay positiveSignal | 673 | 1907.7 | 1654.4 | 357,872 |
| oestrogen receptor assay positiveSignal | 773 | 1584.2 | 1398.9 | 388,853 |
| breast cancer in situSignal | 516 | 505.0 | 451.8 | 153,957 |
| breast cancer femaleSignal | 9,758 | 425.1 | 415.9 | 2,625,218 |
| breast cancer metastaticSignal | 1,380 | 109.0 | 103.2 | 128,712 |
| breast cancerSignal | 8,138 | 70.7 | 69.3 | 512,632 |
| meningiomaSignal | 854 | 42.8 | 39.9 | 32,908 |
| ovarian cancerSignal | 499 | 42.3 | 38.7 | 18,995 |
| cerebrovascular accident | 389 | 1.7 | 1.5 | 112 |
| anxiety | 390 | 1.0 | 0.9 | 0 |
| pain | 521 | 0.6 | 0.6 | 118 |
| headache | 391 | 0.5 | 0.4 | 253 |
| nausea | 470 | 0.4 | 0.4 | 349 |
| fatigue | 448 | 0.4 | 0.4 | 360 |
| drug ineffective | 520 | 0.3 | 0.3 | 953 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.